#32 – Steve Reed, Co-Founder & Chief Executive Officer of HDT Bio

Introduction

In a captivating episode of the BioBreakthroughs podcast, host Jared S. Taylor sat down with Steven G. Reed, CEO and co-founder of HDT Bio. Reed, a seasoned microbiologist and immunologist, shared insights from his 40-year career and the innovative strides HDT Bio is making in the field of vaccines and therapeutics.

Background of a Visionary

Reed’s extensive experience, including his tenure at Cornell Medical School and work in tuberculosis and leprosy, sets the stage for his current mission at HDT Bio. Focusing on viral diseases and cancer, HDT Bio aims to create affordable, state-of-the-art therapeutics and vaccines.

Challenges and Achievements

The conversation delved into the technological and public opinion challenges faced in vaccine development. Reed emphasized the importance of safety, efficacy, and public education in addressing these challenges.

The Amplify Vaccine Platform

A highlight of the interview was Reed’s explanation of HDT Bio’s innovative Amplify vaccine platform. This platform features a unique RNA that expands post-injection, offering a potent immune response with minimal dosage. The platform also includes a specially designed delivery vehicle that enhances safety and efficacy.

Commitment to Affordability and Accessibility

A recurrent theme in Reed’s vision is the commitment to making vaccines affordable and accessible, especially for neglected diseases and underserved populations. He shared his perspective on balancing technological advances with practical considerations like cost and storage.

The Future of HDT Bio

Looking ahead, Reed expressed excitement about HDT Bio’s upcoming projects, particularly in oncology. Their work on a cancer vaccine to prevent brain metastasis in breast cancer patients exemplifies their forward-thinking approach.

Conclusion

Steven G. Reed’s appearance on BioBreakthroughs provides a fascinating glimpse into the world of vaccine development. With its innovative platforms and commitment to accessibility, HDT Bio is at the forefront of creating solutions for today’s health challenges.